Literature DB >> 19795380

Non-invasive detection of glycine as a biomarker of malignancy in childhood brain tumours using in-vivo 1H MRS at 1.5 tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR.

N P Davies1, M Wilson, K Natarajan, Y Sun, L MacPherson, M-A Brundler, T N Arvanitis, R G Grundy, A C Peet.   

Abstract

Management of brain tumours in children would benefit from improved non-invasive diagnosis, characterisation and prognostic biomarkers. Metabolite profiles derived from in-vivo MRS have been shown to provide such information. Studies indicate that using optimum a priori information on metabolite contents in the construction of linear combination (LC) models of MR spectra leads to improved metabolite profile estimation. Glycine (Gly) is usually neglected in such models due to strong overlap with myo-inositol (mI) and a low concentration in normal brain. However, biological studies indicate that Gly is abundant in high-grade brain tumours. This study aimed to investigate the quantitation of Gly in paediatric brain tumours using MRS analysed by LCModel, and its potential as a non-invasive biomarker of malignancy. Single-voxel MRS was performed using PRESS (TR 1500 ms, TE 30 ms/135 ms) on a 1.5 T scanner. Forty-seven cases (18 high grade (HG), 17 low grade (LG), 12 ungraded) were retrospectively selected if both short-TE and long-TE MRS (n = 33) or short-TE MRS and high-resolution magic-angle spinning (HRMAS) of matched surgical samples (n = 15) were available. The inclusion of Gly in LCModel analyses led to significantly reduced fit residues for both short-TE and long-TE MRS (p < 0.05). The Gly concentrations estimated from short-TE MRS were significantly correlated with the long-TE values (R = 0.91, p < 0.001). The Gly concentration estimated by LCModel was significantly higher in HG versus LG tumours for both short-TE (p < 1e-6) and long-TE (p = 0.003) MRS. This was consistent with the HRMAS results, which showed a significantly higher normalised Gly concentration in HG tumours (p < 0.05) and a significant correlation with the normalised Gly concentration measured from short-TE in-vivo MRS (p < 0.05). This study suggests that glycine can be reliably detected in paediatric brain tumours using in-vivo MRS on standard clinical scanners and that it is a promising biomarker of tumour aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19795380     DOI: 10.1002/nbm.1432

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  25 in total

1.  Minimization of spectral pattern changes during HRMAS experiments at 37 degrees celsius by prior focused microwave irradiation.

Authors:  Myriam Davila; Ana Paula Candiota; Martí Pumarola; Carles Arus
Journal:  MAGMA       Date:  2012-10       Impact factor: 2.310

Review 2.  Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases.

Authors:  Christopher Dietz; Felix Ehret; Francesco Palmas; Lindsey A Vandergrift; Yanni Jiang; Vanessa Schmitt; Vera Dufner; Piet Habbel; Johannes Nowak; Leo L Cheng
Journal:  NMR Biomed       Date:  2017-09-15       Impact factor: 4.044

3.  Mapping of glycine distributions in gliomas.

Authors:  A A Maudsley; R K Gupta; R Stoyanova; N A Parra; B Roy; S Sheriff; N Hussain; S Behari
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-30       Impact factor: 3.825

4.  In vivo (1)H MRSI of glycine in brain tumors at 3T.

Authors:  Sandeep K Ganji; Elizabeth A Maher; Changho Choi
Journal:  Magn Reson Med       Date:  2015-02-04       Impact factor: 4.668

5.  Measurement of glycine in gray and white matter in the human brain in vivo by 1H MRS at 7.0 T.

Authors:  Abhishek Banerjee; Sandeep Ganji; Keith Hulsey; Ivan Dimitrov; Elizabeth Maher; Subroto Ghose; Carol Tamminga; Changho Choi
Journal:  Magn Reson Med       Date:  2012-06-12       Impact factor: 4.668

6.  Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors.

Authors:  Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Ivan E Dimitrov; Juan M Pascual; Robert Bachoo; Bruce E Mickey; Craig R Malloy; Elizabeth A Maher
Journal:  Magn Reson Med       Date:  2011-03-09       Impact factor: 4.668

Review 7.  Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring: preclinical and clinical approaches.

Authors:  Risto A Kauppinen; Andrew C Peet
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

Review 8.  Clinical proton MR spectroscopy in central nervous system disorders.

Authors:  Gülin Oz; Jeffry R Alger; Peter B Barker; Robert Bartha; Alberto Bizzi; Chris Boesch; Patrick J Bolan; Kevin M Brindle; Cristina Cudalbu; Alp Dinçer; Ulrike Dydak; Uzay E Emir; Jens Frahm; Ramón Gilberto González; Stephan Gruber; Rolf Gruetter; Rakesh K Gupta; Arend Heerschap; Anke Henning; Hoby P Hetherington; Franklyn A Howe; Petra S Hüppi; Ralph E Hurd; Kantarci Kantarci; Dennis W J Klomp; Roland Kreis; Marijn J Kruiskamp; Martin O Leach; Alexander P Lin; Peter R Luijten; Malgorzata Marjańska; Andrew A Maudsley; Dieter J Meyerhoff; Carolyn E Mountford; Sarah J Nelson; M Necmettin Pamir; Jullie W Pan; Andrew C Peet; Harish Poptani; Stefan Posse; Petra J W Pouwels; Eva-Maria Ratai; Brian D Ross; Tom W Scheenen; Christian Schuster; Ian C P Smith; Brian J Soher; Ivan Tkáč; Daniel B Vigneron; Risto A Kauppinen
Journal:  Radiology       Date:  2014-03       Impact factor: 11.105

9.  ¹H nuclear magnetic resonance spectroscopy characterisation of metabolic phenotypes in the medulloblastoma of the SMO transgenic mice.

Authors:  S K Hekmatyar; M Wilson; N Jerome; R M Salek; J L Griffin; A Peet; R A Kauppinen
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

10.  Diagnostic accuracy and added value of qualitative radiological review of 1H-magnetic resonance spectroscopy in evaluation of childhood brain tumors.

Authors:  Karen A Manias; Simrandip K Gill; Lesley MacPherson; Adam Oates; Benjamin Pinkey; Paul Davies; Niloufar Zarinabad; Nigel P Davies; Ben Babourina-Brooks; Martin Wilson; Andrew C Peet
Journal:  Neurooncol Pract       Date:  2019-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.